Earnings Releases

Date Headline
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
Last patient enrolled ahead of expectations in pivotal trial evaluating zanidatamab as monotherapy in 2L biliary tract cancers (BTC) Two zanidatamab data presentations at ASCO in June: 1L breast cancer and 1L gastroesophageal adenocarcinoma ( GEA ) Presented topoisomerase 1 inhibitor (TOPO1i)  Continue Reading
Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results
Enrollment on track for both pivotal trials of zanidatamab in 1L gastroesophageal adenocarcinoma (GEA) and 2L biliary tract cancer (BTC). Announced submission of abstracts for upcoming clinical data for the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting.  Continue Reading
Copyright 2022 , Zymeworks Inc.